Lead Product(s): Atropine
Therapeutic Area: Ophthalmology Product Name: OT-101
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Morgan Stanley
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering July 10, 2020
Ocumension's IPO marks a significant milestone in its journey to become China's leading ophthalmology platform. Company intent to use these funds to continue expanding its portfolio with innovative new drug assets.